were tested. Staining of paraffin sections was tested without any pretreatment, as well as with heat-based antigen retrieval methods using citrate buffer (10 mM, pH 6.0), EDTA buffer (1 mM, pH 8.0) and commercial retrieval solutions like DAKO-TRS (DAKO, Carpintera, CA), and DAKO hipH. The primary antibody was detected with a biotinylated horse anti-mouse-secondary reagent (1:200; Vector Laboratories, Burlingham, CA) followed by an avidin-biotin-complex system (Vector) using diaminobenzidine tetrahydrochloride (DAB, Biogenex, San Ramon, CA) as a chromogen. The extent of immunohistochemical reactivity in tumour tissues was estimated by light microscopy and graded according to the number of immunoreactive cells in 25% increments: 'focal' indicating staining of single cells or small clusters of cells (not more than 5% cells stained); + = <25%, ++ = 25-50%, +++ = 50-75%, and ++++ = >75% of cells stained. A weak staining intensity was indicated by 'w'. Control slides consisted of testis tissue as a positive control; negative control slides were incubated with buffer instead of MA454.
RT-PCR
In order to determine the specificity of MA454, lung tumours were typed for MAGE-1 by RT-PCR and the results were compared with MA454 immunohistochemical staining. RT-PCR was done as previously described . Briefly, total RNA was extracted from 20 µm sections of corresponding frozen tissue blocks. Testicular tissue was used as a positive control tissue. RNA was reverse transcribed into cDNA and PCR-amplified with AmpliTaqGold (Perkin Elmer, Norwalk, CT) for 30 cycles in a thermal cycler (Perkin Elmer) at an annealing temperature of 60°C. Oligonucleotide primers CHO-12 and CHO-14 were used to detect MAGE-1 (Brasseur et al, 1992) ; both primers were synthesized commercially (GIBCO, Grand Islands, NY). RT-PCR products were visualized with ethidium bromide. In order to confirm the specificity of the RT-PCR products, a sequence analysis was performed commercially (Bioresource Center, Cornell University, Ithaca, NY) for 6 representative tissues (cases #2, #3, #5, #6, #21, #24).
RESULTS

MA454
showed poor reactivity in frozen tissue sections. Reproducible, strong immunoreactivity was observed in formalinfixed, paraffin-embedded standard archival tissue when using an antigen retrieval technique. Hence, further assays were done on formalin-fixed paraffin-embedded tissues. The best staining was achieved after heating sections at 90°C in EDTA for 30 minutes. A biotin/avidin blocking kit (Vector, Elite) was used to suppress the background staining due to endogenous biotin activity. Table 1 summarizes the immunohistochemical staining properties of MA454 in normal tissues. No staining could be observed in any normal tissue except testis. The testicular immunoreactivity was confined to components within the seminiferous tubules and staining was restricted to germ cells. Spermatogonia showed strong immunoreactivity, with a lesser degree of staining in primary spermatocytes. A consistent strong cytoplasmic staining of spermatogonia was observed. Germ cells at later maturation stages, e.g. spermatocytes, showed a more variable labelling of the cytoplasm. This staining varied from none to mostly faint and occasionally moderate in spermatocytes, depending on the concentration of MA454 and the particular specimen used. As with spermatogonia, staining of spermatocytes was cytoplasmic with no significant nuclear reactivity. Spermatids, Sertoli cells, and intertubular tissue components such as Leydig cells remained immunonegative ( Figure 1A, B) . Table 2 summarizes the results of immunohistochemical staining and RT-PCR analysis of the lung tumours. Fifty-nine cases were available for immunohistochemical evaluation. All except one case of carcinosarcoma were non-small cell lung carcinomas. From 54 cases, fresh tissue for RT-PCR analysis was also available. Immunohistochemistry revealed immunopositivity with MA454 in 19/59 cases (32%). However, in the vast majority of tumours, MA454 revealed a predominantly heterogeneous reactivity pattern (Fig. 1C-F) , with 'focal' immunoreactivity (8 cases) or immunoreactivity in <25% of the tumour (7 cases). These tissues showed MA454 positive single tumour cells or small tumour nests (Fig. 1C, F) . Only in 4 tissues was staining seen in wider areas (>25%) of the tumour. One of these 4 cases (Fig. 1D) revealed homogenous immunoreactivity in all neoplastic areas ('++++'). The cellular staining pattern was cytoplasmic and no nuclear staining was observed (Fig. 1E) . Among 37 adenocarcinoma cases in our series, 9 were immunoreactive. Of the 12 squamous cell carcinoma and 9 large cell undifferentiated carcinoma cases, 5 and 4 cases were MA454 positive, respectively. The carcinosarcoma was also MA454 positive. The 4 cases with more widespread MA454-reactivity were two squamous cell carcinomas and two adenocarcinomas. In case 43, two blocks were available for analysis: while one block showed staining in more than 25% of the tumour, the other block revealed a focal staining. RT-PCR showed the presence of MAGE-1 mRNA in 17/54 cases (32%). The sequencing analysis of the RT-PCR products confirmed the presence of MAGE-1 mRNA. The results of RT-PCR typing matched IHC staining in 49 of the 54 cases (91%). Of the 5 cases that did not co-type with MA454 expression, 3 were MAGE-1 mRNA negative and IHC positive, whereas two cases were mRNA positive and MA454 negative. All MA454 positive and MAGE-1 RT-PCR negative cases showed focal immunoreactivity.
DISCUSSION
A number of serological reagents for the evaluation of MAGE protein expression has been generated SchultzThater et al, 1994; Kocher et al, 1995; Takahashi et al, 1995; Carrel et al, 1996; Jurk et al, 1998) . One of the most intensely studied MAGE reagents is 57B, a mAb generated against MAGE-3 recombinant protein (Fischer et al, 1997; Hofbauer et al, 1997; Cheville and Roche, 1999) . Although initially thought to have specificity for MAGE-3, subsequent analysis with COS cells transfected with individual MAGE genes, has shown that 57B detects MAGE-1, -2, -3, -4, -6, and -12 (M Godelaine, personal communication). With regard to MAGE-1, several monoclonal antibodies have developed. Mab 6C1 reacts with MAGE-10 as well as MAGE-1 (Carrel et al, 1996; Rimoldi et al, 1999) , and the fine specificity of 77B has not been reported (Gudat et al, 1996; Zuber et al, 1997) . MA454, the anti-MAGE-1 mAb used in this analysis, originally did not show cross-reactivity with other MAGE proteins . Carrel et al (1996) describing the generation of their anti-MAGE mAb 6C1 included MA454 and did not find any indication of MA454 cross-reacting with other proteins but MAGE-1. Recently, an immunohistochemical analysis of a panel of MAGE-transfected cells, also confirmed that MA454 was specific for MAGE-1 and did not react with MAGE-2, -3, -4, -6, -8, and -9 to -12 (M. Godelaine, manuscript in preparation).
In the initial analysis of MA454, no immunoreactivity could be shown using frozen tumour specimens . However, when antigen retrieval techniques are used, MA454 shows strong reactivity on formalin-fixed paraffin-embedded specimens. Antigen retrieval has only recently become an important tool for immunohistochemistry and is now employed as a standard procedure in pathology (Shi et al, 1996) . At this point, we can only speculate about reasons for recovering MAGE-1 reactivity after antigen retrieval. Possibly the structure of the denatured MAGE-1 recombinant protein used for immunization resembles the antigen present in formalin-fixed, paraffin-embedded tissues after antigen retrieval more closely than its acetone-fixed counterpart. Another possibility is that antigen retrieval exposes epitopes not accessible in acetone-fixed specimens.
In the present study, the immunoreactivity of MA454 with normal tissues closely correlated with the known MAGE-1 mRNA expression pattern (De Plaen et al, 1994) i.e. only testis was immunoreactive. With regard to spermatogenic cells, MA454 staining contrasts with the pattern seen with mAb 57B, anti-MAGE-4 mAb R5 and a MAGE-1 polyclonal reagent (Takahashi et al, 1995; Itoh et al, 1996; Jungbluth et al, 2000) . The latter three mAbs give a strong nuclear staining, while MA454 is confined to the cytoplasm. The staining of later stage germ cells, i.e. spermatocytes, varied, ranging from mostly faint and moderate to no staining, depending on MA454 concentrations and individual specimens. Thus, MAGE-1 protein is present in early stages of germ cell maturation, with the highest level of expression in spermatogonia and decreasing expression levels inversely paralleling germ cell maturation. As little is known about the biological function of the MAGE-proteins, an interpretation of these different staining patterns is difficult. The expression pattern of different MAGE proteins suggests that each gene plays a different role in different stages of germ cell maturation.
In this series of lung neoplasms, frozen and paraffin tissues were available for most cases and side by side immunohistochemistry and RT-PCR typing could be performed. Previous mRNA analyses for MAGE-1 expression of lung tumours have varied widely: 11% (Sakata, 1996) , 20% (Ferlazzo et al, 1996) , 35% (Weynants et al, 1994) , 49% (Van Den Eynde and Van der Bruggen, 1997) or more than 60% (Fischer et al, 1997) . spermatogenic cells, staining was restricted to cytoplasm of the tumour cells and no significant nuclear immunoreactivity was observed. Cytoplasmic localization of the MAGE-1 antigen was previously shown by cell fractionation studies of cultured tumour cells using mAb MA454 (Amar-Costesec et al, 1994) and by immunofluorescence in cultured cells with mAb 77B (SchultzThater et al, 1994; Gudat et al, 1996) . In our immunohistochemical analysis, 4 cases showed expression in >25% of the tumour; only 1 of these gave homogeneous staining. However, most tumours showed a restricted 'focal' staining or immunoreactivity in less than 25% of the tumour. This extreme heterogeneous immunoreactivity likely explains the discrepancy between mRNA-and MA454 expression in 5 cases as due to error variations. This is supported by the fact that all discrepant MA454-positive/RT-PCR negative cases revealed only focal immunoreactivity. Due to the predominance of immunonegative areas, samples could easily contain solely non-reactive cells. Also, degradation of mRNA in tissue specimens cannot be excluded. The heterogeneity with MA454 is more pronounced than we saw in our previous study with mAb 57B (Jungbluth et al, 2000) . This is probably due to the fact that 57B is essentially a polyvalent MAGE reagent. Tumour 43, a case in which 2 paraffin blocks were available for assessment, illustrates the heterogeneous expression of MAGE-1 even in a single patient. While one block showed focal reactivity, the other block revealed immunostaining in almost 50% of the tumour. A similar heterogeneity was observed in a limited number of melanoma specimens with mAb 77B . Genomic demethylation has been associated with the activation of the MAGE-1 gene (De Smet et al, 1996) , but how this relates to expression by some tumours and not by others is unexplained. As homogeneously expressed antigens are preferred targets for immunotherapy, MAGE-1 might not be a sufficient sole target for immunotherapeutic approaches in lung neoplasms. Though mRNA expression analyses might suggest a high percentage of positive tumours for any particular antigen, our investigation demonstrates that an immunohistochemical examination renders a different picture for protein expression and is essential for the evaluation of targets for immunotherapy.
